Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor inhibition where conventional immunotherapy fails. (Nanowerk Spotlight) ...

Worth up to $2.4 billion, the acquisition is also the latest in a series of buyouts involving startups with technologies that modify immune cells inside the body.

Thrombotic disorders—such as ischemic stroke, heart attack, pulmonary embolism, and deep vein thrombosis—are principal contributors to global mortality. However, conventional thrombolytic therapies ...

Eli Lilly (NYSE:LLY) announced an agreement to acquire Orna Therapeutics for up to $2.4b, adding circular RNA and in vivo CAR T technology to its drug development toolkit. The company also expanded ...

Detailed price information for ME Therapeutics Holdings Inc. (METX-CN) from The Globe and Mail including charting and trades.

New research shows that physical pressure from brain tumors or injuries triggers a "self-destruction" program in neurons, leading to irreversible brain damage.

Eli Lilly (LLY) stock acquiring Orna Therapeutics for up to $2.4 billion to develop circular RNA CAR-T therapies for B ...

Researchers developed a silicon-based nanothrombolytic therapy that efficiently dissolves blood clots while controlling the ...

Researchers led by Prof. SHI Jianlin from the Shanghai Institute of Ceramics of the Chinese Academy of Sciences have developed a novel silicon-based nanothrombolytic therapy that achieves efficient ...

A newly published scientific paper titled "Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in ...

The first study on deuterium-depleted water (DDW) concluded that a higher D/H ratio inside cells can trigger cell division. This was supported by lab experiments showing that lowering deuterium levels ...